189 related articles for article (PubMed ID: 23826153)
1. Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
Keane C; O'Shea D; Reiberger T; Peck-Radosavljevic M; Farrell G; Bergin C; Gardiner CM
PLoS One; 2013; 8(6):e66831. PubMed ID: 23826153
[TBL] [Abstract][Full Text] [Related]
2. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
3. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
4. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
6. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.
Dayyeh BK; Gupta N; Sherman KE; de Bakker PI; Chung RT;
PLoS One; 2011; 6(10):e25753. PubMed ID: 22003405
[TBL] [Abstract][Full Text] [Related]
7. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V
AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235
[TBL] [Abstract][Full Text] [Related]
8. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
Arends JE; van Assen S; Stek CJ; Wensing AM; Fransen JH; Schellens IM; Spijkers SN; Mudrikova T; van Baarle D; Sprenger HG; Hoepelman AI
Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513
[TBL] [Abstract][Full Text] [Related]
11. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
12. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
Matas M; Picornell A; Cifuentes C; Payeras A; Homar F; González-Candelas F; López-Labrador FX; Moya A; Ramon C; Castro JA
Int Microbiol; 2014 Mar; 17(1):11-20. PubMed ID: 25296442
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
[TBL] [Abstract][Full Text] [Related]
14. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
[TBL] [Abstract][Full Text] [Related]
15. Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
Neukam K; Munteanu D; Haubitz S; Mira JA; Ingiliz P; Rivero-Juárez A; Lutz T; de los Santos-Gil I; Scholten S; Márquez M; Rauch A; Rockstroh JK; Pineda JA
Antivir Ther; 2015; 20(4):407-13. PubMed ID: 25470790
[TBL] [Abstract][Full Text] [Related]
16. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
[TBL] [Abstract][Full Text] [Related]
17. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM
AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939
[TBL] [Abstract][Full Text] [Related]
18. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
